Grail's Slump Enters Week: Navigating Biotech's Setback
Grail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
Harness the power of social media for personal debt fundraising. Connect with your network and increase your chances of success.
18,294 articlesGrail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
The company behind Claude just filed for an IPO, stirring questions about AI stocks and long-term growth. This guide ...
Investors are watching Bionano Genomics as the company enters 2026 with evolving demand for optical genome mapping. T...
A stock that has surged 1,000% in a year can still offer opportunity — if you know where to look. This guide breaks d...
Archer Aviation sits at a pivotal crossroads as FAA progress updates loom and defense contracts lurk in the wings. Th...
SpaceX kicked off trading with a sharp first-day rally. This guide analyzes historical IPO patterns to estimate where...
When a big shareholder starts selling, the market pays attention. This article explains what this major investor dump...
Two clinical-stage biotech names, two distinct paths to value. This guide breaks down Dyne Therapeutics and Viking Th...
A bold stake in a boutique asset-manager platform is sending ripples through the investing world. This article explai...
What happens when AI breakthroughs and high-flying tech bets collide with political markets? This article explains th...
Investors sent Joby Aviation stock higher after the company topped expectations on its latest results. This article b...
ARK Invest doubled down on SpaceX after a market pullback, funding the move by trimming Alibaba. The trade underscore...